Sign up for a free trial now
  • Login
  • Subscribe
  • Take a FREE Trial
  • About Us
  • Contact us
  • RSS

18 May 2013


The Pharma Letter
  • Home
  • 7 Day Premium Trial
  • Pharmaceuticals
  • Biotechnology
  • Generics
  • Events
  • Companies
  • Drugs
  • Subscribe

tapentadol Articles

Pain therapies sales to exceed $49 billion in 2026, driven by new product launches

16 December 2012

Tapentadol ER has advantages over Lyrica in reducing diabetic neuropathy pain intensity

21 March 2012

Johnson & Johnson’s Nucynta OKed by US FDA for moderate to severe chronic pain

30 August 2011

Grunenthal debuts novel severe pain drug Palexia SR in UK

16 May 2011

J&J’s tapentadol may significantly reduce pain intensity for diabetics with peripheral neuropathy

31 January 2011

Galapagos in deal with Johnson & Johnson unit for oncology target in 33.5 million-euro deal; US FDA delays J&J’s tapentadol ER

5 October 2010

Showing 1-6 of 6 articles

Go to beginningPrevious
  • 1
NextGo to end
  • Hot Topics
  • Most Read
  • Encouraging results with Sangamo's SB-728-T in HIV treatment
  • Bristol-Myers' data on Yervoy and nivolumab causes a stir
  • AstraZeneca plans to move three cancer drug candidates into Ph III
  • Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
  • Merck Serono Ph III trial of L-BLP25 fails endpoint in NSCLC
  • Encouraging results with Sangamo's SB-728-T in HIV treatment
  • Bristol-Myers' data on Yervoy and nivolumab causes a stir
  • AstraZeneca plans to move three cancer drug candidates into Ph III
  • Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
  • Merck Serono Ph III trial of L-BLP25 fails endpoint in NSCLC

30 Day Premium Trial


Events

Twitter Right banner

RSS



© 2013 thepharmaletter.com

  • Home
  • RSS
  • About Us
  • Subscribe
  • Terms and Conditions
  • Article Archive
Site powered by WORKSsitebuilder CMS